AVTX- Avalo Therapeutics, Inc.

Insider activity in AVTX over the last quarter tilts toward selling: insiders offloaded a net 101,317 shares worth roughly $2.0M.

Classified under Biotechnology (Health Care sector), AVTX's insider flows are most useful compared with peers in the same group.

Insider Ownership

Role	Insider	Shares	Value	30d
CEO	Neil Garry Arthur	190.3K	-	-
Other	Boyd Taylor	95.0K	-	-
Other	Doyle Mittie	51.8K	$1.04M	-
CFO	Sullivan Christopher Ryan	39.9K	$651.7K	-
Other	Riley Jennifer	37.0K	$725.6K	-

Buys and sells only

10 filings · page 11

Date	Insider	Role	Type	Shares	Price	Value	Chg%
Mar 27, 2019	Armistice Capital, LLC56	Director, 10% Owner	Buy	50,000	$5.47	$273,299.04	+0.3%
Mar 8, 2019	Armistice Capital, LLC56	Director, 10% Owner	Buy	374,486	$5.50	$2,059,313.95	+2.1%
Jan 11, 2019	Armistice Capital, LLC56	Director, 10% Owner	Buy	13,996	$3.88	$54,335.40	-
Jan 8, 2019	Armistice Capital, LLC56	Director, 10% Owner	Buy	27,004	$3.48	$93,913.80	+0.1%
Dec 31, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	38,799	$3.14	$121,757.67	+0.2%
Dec 18, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	50,000	$3.31	$165,407.81	+0.3%
Dec 10, 2018	Phillips Matthew V	Chief Commercial Officer	Buy	497	$2.85	$1,415.21	New
Dec 10, 2018	Harrell James Archie Jr	Exec. VP, Mktg &External Comm	Buy	4,156	$2.85	$11,834.21	New
Dec 10, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	36,400	$3.41	$124,145.63	+0.2%
Dec 4, 2018	Armistice Capital, LLC56	Director, 10% Owner	Buy	25,797	$3.49	$90,153.37	+0.1%